<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02160301</url>
  </required_header>
  <id_info>
    <org_study_id>13-2669</org_study_id>
    <nct_id>NCT02160301</nct_id>
  </id_info>
  <brief_title>Effect of a Multimodal Pain Regimen on Pain Control, Patient Satisfaction and Narcotic Use in Orthopaedic Trauma Patients</brief_title>
  <official_title>Effect of a Multimodal Pain Regimen on Pain Control, Patient Satisfaction and Narcotic Use in Orthopaedic Trauma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective, randomized, open-label comparison of a multimodal regimen and a
      standard, narcotic-based regimen for postoperative pain control in patients undergoing
      surgery for an operatively indicated, isolated extremity fracture. The investigators will be
      measuring pain levels, narcotic use, patient satisfaction, patient reported function, adverse
      events and fracture union. The investigators hypothesize that this multimodal regimen will
      lead to improved pain, less narcotic use and improved satisfaction as compared to the
      standard regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be assessed for inclusion or exclusion during admission to the hospital or
      during evaluation in the clinic or emergency room for an isolated extremity fracture for
      which surgery is indicated. Once enrolled in the study and consent obtained, patients will be
      randomized into either the standard therapy group or the multimodal therapy group using
      permuted block randomization based on injury site. The sites of fracture are as follows:

        -  wrist/hand/forearm

        -  elbow/upper arm/shoulder

        -  acetabulum/pelvis

        -  foot/ankle

        -  patella/tibia (shaft, proximal)

        -  femur (proximal to distal)

      The investigators have assumed that these distinct areas result in a similar amount of
      disability and pain as compared to the other sites. This is an attempt to mitigate the
      possible confounder of disproportionate numbers of more painful or more debilitating injuries
      falling in one study group compared to another.

      Pre-operatively, patient demographic data will be recording including age, gender, BMI, hand
      dominance, occupation, use of tobacco/alcohol/illicit drugs, use of assistive devices,
      relevant comorbidities (i.e., diabetes), site of injury, mechanism and energy (high or low).
      If there is to be a delay between initial presentation and surgery, as is often the case for
      distal radius or ankle fractures, among others, multimodal patients will begin their therapy
      immediately after evaluation. Thus, they will be started on scheduled 1000mg acetaminophen
      and 100mg gabapentin both three times daily. They will also be provided an 5mg oxycodone
      prescription with instructions to take 1-3 tablets every 4 hours as needed for pain. Standard
      therapy patients will be prescribed oxycodone alone, using the same parameters, with the
      ability to take acetaminophen on an as needed basis.

      Pre-operatively, multimodal patients will receive 1000mg IV acetaminophen, 100mg PO
      gabapentin and 400mg PO celecoxib. All patients will have a peripheral nerve block placed
      when indicated, to confirm to the investigators standard of care. Patients will then undergo
      surgery with the investigators standardized anesthesia protocol as described in the protocol.
      Intraoperatively, multimodal patients will receive 8mg of IV dexamethasone. Post-operatively,
      multimodal patients will be given 1000mg acetaminophen three times daily for the duration of
      their narcotic use and 100mg Gabapentin three times daily for 1 week, which will be titrated
      to 200mg three times daily for 1 additional week. They will also receive an oxycodone
      prescription as described previously. Standard therapy patients will be given an oxycodone
      prescription alone with the advice to take tylenol on an as needed basis not to exceed
      4000mg/day. No placebo medications will be used as this is an open label study.

      Patients will be instructed to avoid all anti-inflammatory medications. All patients across
      groups will be given aspirin 81mg for deep vein thrombosis prophylaxis if they suffered a
      lower extremity fracture. Should a patient require an alternative deep vein thrombosis
      prophylaxis regimen due to an allergy to aspirin or a personal history of deep vein
      thromboses, low molecular weight heparin will be used.

      Patients will be given a diary to record their daily narcotic use, daily minimum, maximum and
      average pain scores using a visual analog scale and any side effects. Patients will be
      provided the contact information of the attending surgeon's nurse to report any serious
      allergies or adverse effects of the study medications. A case by case decision will be made
      to either continue the protocol or to drop the patient from the study and make needed
      medications changes.

      Patients will be followed at defined time points after surgery including, 2 wks, 6wks, 3mo
      and 6mo.

      At their 2 wk follow up visit they will fill out the Short Musculoskeletal Function
      Assessment for their preoperative functional state as well as the American Pain Society
      Patient Satisfaction Questionnaire. These will again be filled out at their 3 and 6 month
      visits. Union will be assessed at their 3 and 6 month visits by a third party, blinded
      observed. It will be defined as three cortices of bridging callus on 2 orthogonal views. Once
      fracture union occurs or nonunion is identified control patients will be allowed to use non
      steroidal anti-inflammatories as needed. Time to return to work/normal activity, total
      narcotic usage and duration of narcotic use will also be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Insufficient infrastructure/funding for enrollment
  </why_stopped>
  <start_date type="Anticipated">November 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>6 months</time_frame>
    <description>VAS score for pain control, daily for two weeks post op and at all follow up visits for 6 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Narcotic Use</measure>
    <time_frame>2 months</time_frame>
    <description>Measurement of both daily narcotic use in milligrams as well as the duration of narcotic treatment in days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>3 months</time_frame>
    <description>Measurement of patient satisfaction with pain control regimen using the American Pain Society's Patient Outcome Questionnaire (APS-POQ).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient function</measure>
    <time_frame>6 months</time_frame>
    <description>Measurement of patient function using the Short Musculoskeletal Functional Assessment questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fracture Union</measure>
    <time_frame>6 months</time_frame>
    <description>Binary determination of fracture union (yes or no) during the 6 month duration of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Measurement of the rate of adverse events post operatively.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Post Operative Pain Control</condition>
  <arm_group>
    <arm_group_label>Multimodal pain control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxycodone 5-15mg PO q4hrs prn pre- and post-op, Acetaminophen 1000mg IV once pre-op, Acetaminophen 1000mg PO q8hrs pre-op and x2 weeks post op, prn thereafter, Gabapentin 100mg/200mg PO a8hrs pre-op and x2 weeks post op, Dexamethasone 8mg IV once intra-op, Celecoxib 400mg PO once pre-op.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard pain control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxycodone 5-15mg PO q4hrs prn, Acetaminophen 1000mg PO q8hrs prn.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>PO</description>
    <arm_group_label>Multimodal pain control</arm_group_label>
    <other_name>Neurontin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>PO</description>
    <arm_group_label>Multimodal pain control</arm_group_label>
    <arm_group_label>Standard pain control</arm_group_label>
    <other_name>Tylenol</other_name>
    <other_name>Acephen</other_name>
    <other_name>Cetafen</other_name>
    <other_name>Mapap</other_name>
    <other_name>Q-Pap</other_name>
    <other_name>Valorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>IV</description>
    <arm_group_label>Multimodal pain control</arm_group_label>
    <other_name>Ofirmev</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>PO</description>
    <arm_group_label>Multimodal pain control</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>IV</description>
    <arm_group_label>Multimodal pain control</arm_group_label>
    <other_name>Baycadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>PO</description>
    <arm_group_label>Multimodal pain control</arm_group_label>
    <arm_group_label>Standard pain control</arm_group_label>
    <other_name>Roxicodone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Bone fracture

          -  Isolated injury

          -  Requires operative intervention

        Exclusion Criteria:

          -  pathological fractures

          -  inability to personally consent to participation due to cognitive impairment,
             intoxication or sedation

          -  severe head injury

          -  polytrauma patients with multiple fractures or other injuries

          -  pregnancy

          -  open fractures

          -  metabolic bone disease

          -  allergies or contraindications to the study medications, including sulfa medications.

          -  prior or current drug or alcohol dependence or abuse

          -  liver or kidney disease

          -  physician directed narcotic use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert F Ostrum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNC Chapel Hill Hospital</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kang H, Ha YC, Kim JY, Woo YC, Lee JS, Jang EC. Effectiveness of multimodal pain management after bipolar hemiarthroplasty for hip fracture: a randomized, controlled study. J Bone Joint Surg Am. 2013 Feb 20;95(4):291-6. doi: 10.2106/JBJS.K.01708.</citation>
    <PMID>23302898</PMID>
  </reference>
  <reference>
    <citation>Maheshwari AV, Boutary M, Yun AG, Sirianni LE, Dorr LD. Multimodal analgesia without routine parenteral narcotics for total hip arthroplasty. Clin Orthop Relat Res. 2006 Dec;453:231-8.</citation>
    <PMID>17031312</PMID>
  </reference>
  <reference>
    <citation>Kashefi P, Honarmand A, Safavi M. Effects of preemptive analgesia with celecoxib or acetaminophen on postoperative pain relief following lower extremity orthopedic surgery. Adv Biomed Res. 2012;1:66. doi: 10.4103/2277-9175.100197. Epub 2012 Aug 28.</citation>
    <PMID>23459777</PMID>
  </reference>
  <reference>
    <citation>Panah Khahi M, Yaghooti AA, Marashi SH, Nadjafi A. Effect of pre-emptive gabapentin on postoperative pain following lower extremity orthopaedic surgery under spinal anaesthesia. Singapore Med J. 2011 Dec;52(12):879-82.</citation>
    <PMID>22159930</PMID>
  </reference>
  <reference>
    <citation>Montazeri K, Kashefi P, Honarmand A. Pre-emptive gabapentin significantly reduces postoperative pain and morphine demand following lower extremity orthopaedic surgery. Singapore Med J. 2007 Aug;48(8):748-51.</citation>
    <PMID>17657384</PMID>
  </reference>
  <reference>
    <citation>Ho KY, Gan TJ, Habib AS. Gabapentin and postoperative pain--a systematic review of randomized controlled trials. Pain. 2006 Dec 15;126(1-3):91-101. Epub 2006 Jul 18. Review.</citation>
    <PMID>16846695</PMID>
  </reference>
  <reference>
    <citation>Yadeau JT, Paroli L, Kahn RL, Jules-Elysee KM, Lasala VR, Liu SS, Lin E, Powell K, Buschiazzo VL, Wukovits B, Roberts MM, Levine DS. Addition of pregabalin to multimodal analgesic therapy following ankle surgery: a randomized double-blind, placebo-controlled trial. Reg Anesth Pain Med. 2012 May-Jun;37(3):302-7. doi: 10.1097/AAP.0b013e31824c6846.</citation>
    <PMID>22476240</PMID>
  </reference>
  <reference>
    <citation>Khalili G, Janghorbani M, Saryazdi H, Emaminejad A. Effect of preemptive and preventive acetaminophen on postoperative pain score: a randomized, double-blind trial of patients undergoing lower extremity surgery. J Clin Anesth. 2013 May;25(3):188-92. doi: 10.1016/j.jclinane.2012.09.004. Epub 2013 Apr 6.</citation>
    <PMID>23567482</PMID>
  </reference>
  <reference>
    <citation>Rajpal S, Gordon DB, Pellino TA, Strayer AL, Brost D, Trost GR, Zdeblick TA, Resnick DK. Comparison of perioperative oral multimodal analgesia versus IV PCA for spine surgery. J Spinal Disord Tech. 2010 Apr;23(2):139-45. doi: 10.1097/BSD.0b013e3181cf07ee.</citation>
    <PMID>20375829</PMID>
  </reference>
  <reference>
    <citation>Hebl JR, Dilger JA, Byer DE, Kopp SL, Stevens SR, Pagnano MW, Hanssen AD, Horlocker TT. A pre-emptive multimodal pathway featuring peripheral nerve block improves perioperative outcomes after major orthopedic surgery. Reg Anesth Pain Med. 2008 Nov-Dec;33(6):510-7.</citation>
    <PMID>19258965</PMID>
  </reference>
  <reference>
    <citation>Cho CH, Song KS, Min BW, Lee KJ, Ha E, Lee YC, Lee YK. Multimodal approach to postoperative pain control in patients undergoing rotator cuff repair. Knee Surg Sports Traumatol Arthrosc. 2011 Oct;19(10):1744-8. doi: 10.1007/s00167-010-1294-y. Epub 2010 Oct 19.</citation>
    <PMID>20957469</PMID>
  </reference>
  <reference>
    <citation>Goldstein RY, Montero N, Jain SK, Egol KA, Tejwani NC. Efficacy of popliteal block in postoperative pain control after ankle fracture fixation: a prospective randomized study. J Orthop Trauma. 2012 Oct;26(10):557-61. Erratum in: J Orthop Trauma. 2013 Mar;27(3):181.</citation>
    <PMID>22732860</PMID>
  </reference>
  <reference>
    <citation>VanDenKerkhof EG, Hopman WM, Goldstein DH, Wilson RA, Towheed TE, Lam M, Harrison MB, Reitsma ML, Johnston SL, Medd JD, Gilron I. Impact of perioperative pain intensity, pain qualities, and opioid use on chronic pain after surgery: a prospective cohort study. Reg Anesth Pain Med. 2012 Jan-Feb;37(1):19-27. doi: 10.1097/AAP.0b013e318237516e.</citation>
    <PMID>22157741</PMID>
  </reference>
  <reference>
    <citation>Carroll I, Barelka P, Wang CK, Wang BM, Gillespie MJ, McCue R, Younger JW, Trafton J, Humphreys K, Goodman SB, Dirbas F, Whyte RI, Donington JS, Cannon WB, Mackey SC. A pilot cohort study of the determinants of longitudinal opioid use after surgery. Anesth Analg. 2012 Sep;115(3):694-702. doi: 10.1213/ANE.0b013e31825c049f. Epub 2012 Jun 22.</citation>
    <PMID>22729963</PMID>
  </reference>
  <reference>
    <citation>Lamplot JD, Wagner ER, Manning DW. Multimodal pain management in total knee arthroplasty: a prospective randomized controlled trial. J Arthroplasty. 2014 Feb;29(2):329-34. doi: 10.1016/j.arth.2013.06.005. Epub 2013 Jul 11.</citation>
    <PMID>23850410</PMID>
  </reference>
  <reference>
    <citation>Remérand F, Le Tendre C, Baud A, Couvret C, Pourrat X, Favard L, Laffon M, Fusciardi J. The early and delayed analgesic effects of ketamine after total hip arthroplasty: a prospective, randomized, controlled, double-blind study. Anesth Analg. 2009 Dec;109(6):1963-71. doi: 10.1213/ANE.0b013e3181bdc8a0.</citation>
    <PMID>19923527</PMID>
  </reference>
  <reference>
    <citation>Ayalon O, Liu S, Flics S, Cahill J, Juliano K, Cornell CN. A multimodal clinical pathway can reduce length of stay after total knee arthroplasty. HSS J. 2011 Feb;7(1):9-15. doi: 10.1007/s11420-010-9164-1. Epub 2010 May 22.</citation>
    <PMID>22294952</PMID>
  </reference>
  <reference>
    <citation>Fu PL, Xiao J, Zhu YL, Wu HS, Li XH, Wu YL, Qian QR. Efficacy of a multimodal analgesia protocol in total knee arthroplasty: a randomized, controlled trial. J Int Med Res. 2010 Jul-Aug;38(4):1404-12.</citation>
    <PMID>20926013</PMID>
  </reference>
  <reference>
    <citation>Ho KY, Tay W, Yeo MC, Liu H, Yeo SJ, Chia SL, Lo NN. Duloxetine reduces morphine requirements after knee replacement surgery. Br J Anaesth. 2010 Sep;105(3):371-6. doi: 10.1093/bja/aeq158. Epub 2010 Jun 23.</citation>
    <PMID>20573635</PMID>
  </reference>
  <reference>
    <citation>Rasmussen ML, Mathiesen O, Dierking G, Christensen BV, Hilsted KL, Larsen TK, Dahl JB. Multimodal analgesia with gabapentin, ketamine and dexamethasone in combination with paracetamol and ketorolac after hip arthroplasty: a preliminary study. Eur J Anaesthesiol. 2010 Apr;27(4):324-30. doi: 10.1097/EJA.0b013e328331c71d.</citation>
    <PMID>19734790</PMID>
  </reference>
  <reference>
    <citation>Huang YM, Wang CM, Wang CT, Lin WP, Horng LC, Jiang CC. Perioperative celecoxib administration for pain management after total knee arthroplasty - a randomized, controlled study. BMC Musculoskelet Disord. 2008 Jun 3;9:77. doi: 10.1186/1471-2474-9-77.</citation>
    <PMID>18519002</PMID>
  </reference>
  <reference>
    <citation>Woolf CJ, Chong MS. Preemptive analgesia--treating postoperative pain by preventing the establishment of central sensitization. Anesth Analg. 1993 Aug;77(2):362-79. Review.</citation>
    <PMID>8346839</PMID>
  </reference>
  <reference>
    <citation>Aida S, Fujihara H, Taga K, Fukuda S, Shimoji K. Involvement of presurgical pain in preemptive analgesia for orthopedic surgery: a randomized double blind study. Pain. 2000 Feb;84(2-3):169-73.</citation>
    <PMID>10666521</PMID>
  </reference>
  <reference>
    <citation>Jensen MP, Chen C, Brugger AM. Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain. J Pain. 2003 Sep;4(7):407-14.</citation>
    <PMID>14622683</PMID>
  </reference>
  <reference>
    <citation>Woodside JR. Female smokers have increased postoperative narcotic requirements. J Addict Dis. 2000;19(4):1-10.</citation>
    <PMID>11110060</PMID>
  </reference>
  <reference>
    <citation>Göröcs TS, Lambert M, Rinne T, Krekler M, Modell S. Efficacy and tolerability of ready-to-use intravenous paracetamol solution as monotherapy or as an adjunct analgesic therapy for postoperative pain in patients undergoing elective ambulatory surgery: open, prospective study. Int J Clin Pract. 2009 Jan;63(1):112-20. doi: 10.1111/j.1742-1241.2008.01914.x.</citation>
    <PMID>19125998</PMID>
  </reference>
  <reference>
    <citation>He BJ, Tong PJ, Li J, Jing HT, Yao XM. Auricular acupressure for analgesia in perioperative period of total knee arthroplasty. Pain Med. 2013 Oct;14(10):1608-13. doi: 10.1111/pme.12197. Epub 2013 Jul 18.</citation>
    <PMID>23865512</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2014</study_first_submitted>
  <study_first_submitted_qc>June 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2014</study_first_posted>
  <last_update_submitted>May 17, 2017</last_update_submitted>
  <last_update_submitted_qc>May 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pain</keyword>
  <keyword>postoperative</keyword>
  <keyword>multimodal</keyword>
  <keyword>satisfaction</keyword>
  <keyword>narcotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Narcotics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

